Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
Jérôme Tamburini(Centre National de la Recherche Scientifique), Didier Bouscary(Université Paris Cité), Alexa S. Green(Délégation Paris 5), Patrick Mayeux(Université Paris Cité), Sophie Park(Centre Hospitalier Universitaire de Grenoble), Norbert Ifrah(Institut National du Cancer), Nicolas Chapuis(Délégation Paris 5), Valérie Bardet(Délégation Paris 5), Catherine Lacombe(Centre National de la Recherche Scientifique), Madalina Uzunov(Sorbonne Université), François Dreyfus(Université Paris-Sud), Lise Willems(Hôpital Cochin)
Cited by 185
Related Papers
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
|Leukemia|2011|464